August 06,2024

Milestone: EnitiateBio QY201 Tablets for Moderate to Severe Atopic Dermatitis Phase II clinical trial reaches primary endpoint

Enitiate Bio has achieved its primary endpoint in the Phase II clinical trial of QY201 Tablets, a Class 1 innovative drug independently developed by Enitiate Bio, for the treatment of moderate-to-severe atopic dermatitis, with statistically significant and clinically meaningful results, as well as favorable safety and tolerability.

August 18,2023

Setting Sail for the Sea – FDA Filing the IND Approval for QY201 of EnitiateBio

On July 26, 2023, Beijing time, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as "EnitiateBio" or "Qiyuan") received the IND approval for QY201 from the FDA. This is the first clinical approval obtained by EnitiateBio from the FDA and the first U.S. IND application that was fulfilled by EnitiateBio on its own, marking the official launch of the overseas expansion plan of EnitiateBio QY201.

June 07,2023

Good News！ E-nitiate Biopharmaceuticals Biologics was elected as the vice chairman of Pharma-Derma-Alliance, CEO Kevin Ding was elected Vice Chairman of Pharma-Derma-Alliance

On June 2, the inaugural meeting of thePharma-Derma-Alliance (PhDA) and the first Dermatology New Drug Clinical Research Summit Forum were held in Beijing; the alliance aims to strengthen synergistic innovation and scientific innovation in dermatology clinical research, new drug development and results transformation, and promote the linkage of "government, industry, academia, research and medicine", so as to promote the high-quality development and globalization of the dermatology innovative drug industry. The Alliance aims to promote the development and globalization of the dermatology innovative drug industry to benefit dermatology patients in China and around the world.

April 28,2023

QY211 gel has completed first dose enrollment in Phase Ia healthy subjects

("QYB") is conducting a Phase I clinical study to evaluate the safety and preliminary efficacy of QY211 gel for the treatment of mild to moderate atopic dermatitis in healthy Chinese subjects and patients with mild to moderate atopic dermatitis. The study, officially launched on March 8, 2023, is led by Huashan Hospital of Fudan University with Professors Jing Zhang and Jinhua Xu as principal investigators, and the project is being conducted simultaneously at multiple centers across China.

April 28,2023

QY201 Tablets for Moderate to Severe Atopic Dermatitis in Phase Ib/II Clinical Trial Completes First Patient Enrollment (FPI)

(hereinafter referred to as "QYB") announced that the first patient enrollment (FPI) has been successfully completed in the Chinese Phase Ib/II clinical trial of QY201 tablets, an innovative drug for the treatment of moderate-to-severe atopic dermatitis, and the Phase Ia study of QY201 tablets in healthy subjects was completed at the end of September. Data lock.

April 27,2023

E-nitiate Biopharmaceuticals Biologics Completes Series A Financing of 100 Million RMB In-depth layout around skin and autoimmune disease

(hereinafter referred to as "QYB") announced the completion of a Series A financing round of 100 million RMB, led by Time Investment and followed by Taikun Fund, Linping State Investment and Hangzhou Golden Investment Industry Fund. This round of financing will be used to advance the clinical development of several pipelines, including QY201 and QY101, and further help the company expand its R&D pipeline.

December 11,2020

New Project Dynamics ｜ E-nitiate Biopharmaceuticals Settlement and Betta Fund Strategic Investment Signing Ceremony Successfully Held

On December 10th, the signing ceremony of E-nitiate Biopharmaceuticals settlement and Betta fund strategic investment was successfully held in Yuhang District, Hangzhou. Zhu Zhenwei, member of the Standing Committee of Yuhang District Party committee, Secretary of the Party Working Committee and director of the Management Committee of the Development Zone, Dr. Ding lieming, chairman and CEO of Betta pharmaceutical and founder of Betta fund, and Dr. Shen Wang, chairman and chief scientist of E-nitiate Biopharmaceuticals attended the ceremony.